Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

High-Resolution Genomic Profiling of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) Identified Novel Recurrent Copy Number Variations Involved in Both Pathogenesis and Resistance to Tyrosine Kinase Inhibitors.

Ilaria Iacobucci, E. Ottaviani, A. Astolfi, S. Soverini, N. Testoni, S. Paolini, P.P. Piccaluga, C. Papayannidis, D. Cilloni, A. Pession, F. Pane, A. Vitale, S. Chiaretti, R. Foà, M. Baccarani, Giovanni Martinelli

Blood (2007) 110 (11): 230.

https://doi.org/10.1182/blood.V110.11.230.230

Published: 2007

Journal Articles

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

C. Gambacorti-Passerini, MD, H. Kantarjian, MD, T. Bruemmendorf, MD, G. Martinelli, MD, M. Baccarani, MD, T. Fischer, MD, E.M. Pogliani, MD, B. Hewes, MD, A.D.G. Volkert, MD, N. Bardy-Bouxin, MD, J. Cortes, MD

Blood (2007) 110 (11): 473.

https://doi.org/10.1182/blood.V110.11.473.473

Published: 2007

Journal Articles

The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors.

Blood (2007) 110 (11): 722.

https://doi.org/10.1182/blood.V110.11.722.722

Published: 2007

Journal Articles

Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM.

Carolina Terragna, M. Renzulli, D. Remondini, E. Tagliafico, E. Roncaglia, P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, M. Ceccolini, Giovanni Martinelli, M. Baccarani, M. Cavo

Blood (2006) 108 (11): 245.

https://doi.org/10.1182/blood.V108.11.245.245

Published: 2006

Journal Articles

Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.

Alan K. Burnett, M. Baccarani, Peter Johnson, John Yin, Andrew Saunders, Nigel Russell, Robert Hills

Blood (2006) 108 (11): 1985.

https://doi.org/10.1182/blood.V108.11.1985.1985

Published: 2006

Journal Articles

CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.

Matteo Renzulli, C. Terragna, N. Testoni, E. Montanari, P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, Giovanni Martinelli, M. Baccarani, M. Cavo

Blood (2006) 108 (11): 371.

https://doi.org/10.1182/blood.V108.11.371.371

Published: 2006

Journal Articles

A Phase II Study (Biov-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.

Alan K. Burnett, M. Baccarani, Peter Johnson, John Yin, Andrew Saunders, Nigel Russell, Robert K. Hills

Blood (2006) 108 (11): 425.

https://doi.org/10.1182/blood.V108.11.425.425

Published: 2006

Journal Articles

High Levels of Tumor Load Reduction after Intensive Chemotherapy Favorably Affect the Prognosis of BCR/ABL+ ALL Adult Patients Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

G. Cimino, MD, L. Elia, PhD, Fabrizio Pane, MD, M. Vignetti, MD, P. Fazi, MD, S. Iacobelli, PhD, G. Meloni, MD, A. Vitale, MD, V. Martini, MD, G. Martinelli, MD, F. Di Raimondo, MD, M. Bonifacio, MD, F. Fabbiano, MD, G. Saglio, MD, M. Baccarani, MD, R. Foà, MD, F. Mandelli, MD

Blood (2006) 108 (11): 638.

https://doi.org/10.1182/blood.V108.11.638.638

Published: 2006

Journal Articles

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Ilaria Iacobucci, Giovanni Martinelli, M. Amabile, A. Poerio, S. Soverini, F. Castagnetti, S. Colarossi, A. Gnani, N. Testoni, M. Breccia, E. Abruzzese, B. Martino, D. Cilloni, G. Saglio, F. Pane, G. Rosti, M. Baccarani

Blood (2006) 108 (11): 2156.

https://doi.org/10.1182/blood.V108.11.2156.2156

Published: 2006

Journal Articles

Insuline-Like Growth Factor 1 Is over Expressed in Multiple Myeloma Plasma Cells and Regulates the Expression of the Insuline-Like Growth Factor 1 Receptor.

C. Terragna, M. Renzulli, N. Testoni, T. Grafone, P. Tosi, E. Zamagni, C. Cellini, E. Ottaviani, S. Colarossi, I. Iacobucci, A. Poerio, G. Martinelli, M. Baccarani, M. Cavo

Blood (2005) 106 (11): 4363.

https://doi.org/10.1182/blood.V106.11.4363.4363

Published: 2005

Journal Articles

Iron Chelation Efficiency of Deferasirox (Exjade®, ICL670) in Patients with Transfusional Hemosiderosis.

J. Porter, C. Borgna-Pignatti, M. Baccarani, A. Saviano, S. Abish, R. Malizia, H. Nick, H. Opitz, B. Rabault, I. Gathmann, P. Marks

Blood (2005) 106 (11): 2690.

https://doi.org/10.1182/blood.V106.11.2690.2690

Published: 2005

Journal Articles

Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.

Blood (2005) 106 (11): 4962.

https://doi.org/10.1182/blood.V106.11.4962.4962

Published: 2005

Journal Articles

PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study.

Blood (2005) 106 (11): 2600.

https://doi.org/10.1182/blood.V106.11.2600.2600

Published: 2005

Journal Articles

Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.

Andreas Hochhaus, M. Baccarani, C. Sawyers, A. Nagler, T. Facon, S.L. Goldberg, F. Cervantes, R.A. Larson, M. Voi, R. Ezzeddine, H. Kantarjian

Blood (2005) 106 (11): 41.

https://doi.org/10.1182/blood.V106.11.41.41

Published: 2005

Journal Articles

Earlier Administration of Rituximab Allows Higher Rate of Long-Lasting Response in Adult Patients with Autoimmune Thrombocytopenia.

Francesco F. Zaja, MD, Nicola N. Vianelli, MD, Marta M. Battista, MD, Alessandra A. Sperotto, MD, Francesca F. PAtriarca, MD, Valentina V. Tomadini, MD, Carla C. Fili, MD, M. Tani, MD, Michele M. Baccarani, MD, Renato R. Fanin, MD

Blood (2005) 106 (11): 3991.

https://doi.org/10.1182/blood.V106.11.3991.3991

Published: 2005

Journal Articles

Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.

Blood (2004) 104 (11): 1523.

https://doi.org/10.1182/blood.V104.11.1523.1523

Published: 2004

Journal Articles

Risk of hepatitis C virus infection, Waldenstrom's macroglobulinemia, and monoclonal gammopathies [letter; comment]

F Silvestri, G Barillari, R Fanin, F Zaja, L Infanti, F Patriarca, M Baccarani, C Pipan, E Falasca, GA Botta

Blood (1996) 88 (3): 1125–1126.

https://doi.org/10.1182/blood.V88.3.1125b.1125b

Published: 1996

Journal Articles

Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha [letter]

J Hasford, M Baccarani, R Hehlmann, H Anseri, S Tura, E Zuffa

Blood (1996) 87 (12): 5384–5391.

https://doi.org/10.1182/blood.V87.12.5384.bloodjournal87125384

Published: 1996

Journal Articles

Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders

F Silvestri, C Pipan, G Barillari, F Zaja, R Fanin, L Infanti, D Russo, E Falasca, GA Botta, M Baccarani

Blood (1996) 87 (10): 4296–4301.

https://doi.org/10.1182/blood.V87.10.4296.bloodjournal87104296

Published: 1996

Journal Articles

Alpha-interferon in the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia [letter; comment]

S Tura, M Baccarani

Blood (1995) 85 (10): 2999–3002.

https://doi.org/10.1182/blood.V85.10.2999.bloodjournal85102999

Published: 1995

NARROW

High-Resolution Genomic Profiling of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) Identified Novel Recurrent Copy Number Variations Involved in Both Pathogenesis and Resistance to Tyrosine Kinase Inhibitors.

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors.

Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM.

Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.

CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.

A Phase II Study (Biov-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.

High Levels of Tumor Load Reduction after Intensive Chemotherapy Favorably Affect the Prognosis of BCR/ABL+ ALL Adult Patients Receiving Imatinib Mesylate Alone as a Post-Consolidation Treatment According to the Italian GIMEMA LAL 0201/A Protocol.

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Insuline-Like Growth Factor 1 Is over Expressed in Multiple Myeloma Plasma Cells and Regulates the Expression of the Insuline-Like Growth Factor 1 Receptor.

Iron Chelation Efficiency of Deferasirox (Exjade®, ICL670) in Patients with Transfusional Hemosiderosis.

Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.

PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study.

Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.

Earlier Administration of Rituximab Allows Higher Rate of Long-Lasting Response in Adult Patients with Autoimmune Thrombocytopenia.

Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.

Risk of hepatitis C virus infection, Waldenstrom's macroglobulinemia, and monoclonal gammopathies [letter; comment]

Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha [letter]

Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders

Alpha-interferon in the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia [letter; comment]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only